Author review tools

 Quick Explanation Copied

 Long Explanation

Evidence supporting scientific strength

The supplied records identify a coherent computational-biology trajectory spanning RNA–RNA interaction prediction, biological-network alignment, CRISPR guide-activity modelling, and ribosome biology. Several works are first-author contributions, including RIsearch2 and BEAMS, while other highly cited studies list Alkan as a contributing author. The strongest directly reviewed evidence is the 2022 dripARF study: it combines Ribo-seq, differential analysis, structural proximity mapping, enrichment testing, public datasets, and openly available code. It recovered known heterogeneous ribosome populations and predicted eS25/RPS25 differences in five of six fetal-versus-adult tissue comparisons, while explicitly acknowledging protocol, cross-species, structural-resolution, and directionality limitations. NonedripARF evidence and limitations

Track record and methodological profile

OpenAlex attributes the apparent primary Ferhat Alkan identity (ORCID 0000-0001-6709-9605) 43 works, 1,015 citations, and an h-index of 14; another supplied database reports 33 papers, 858 citations, and an h-index of 13. This discrepancy is a data-integration warning rather than evidence of misconduct: author disambiguation, database coverage, citation timing, and work-count rules can differ. The record includes cited contributions on CRISPR off-target prediction, RNA–protein networks, RNA–RNA interaction prediction, and CRISPR guide activity, suggesting breadth and sustained technical relevance. NoneCRISPR off-target modelling NoneRNA-interaction computation

Critical qualification

The evidence justifies describing Alkan as an accomplished computational and molecular-biology contributor, but not as definitively world-class on author-level evidence alone. Citation counts measure uptake, not validity; coauthorship makes individual intellectual and experimental contributions difficult to infer; and only one paper has been supplied with detailed claim-level evidence. The most important unresolved issue is whether inferred ribosome heterogeneity consistently survives direct protein-composition assays, independent laboratories, and diverse Ribo-seq protocols. Confidence: moderate.

 BGPT Author Review

Scientific Quality

Strong publication and citation record, multiple first-author computational contributions, and evidence of technically sophisticated, testable methods. The score is restrained because complete contribution statements, full-text evaluation across the portfolio, replication evidence, and independent validation are incomplete; citation metrics alone cannot establish scientific correctness.

Communication Quality

The supplied papers appear to communicate complex computational and molecular questions through defined methods, benchmarks, validation datasets, and explicit limitations. A higher score cannot be justified without systematically reviewing the full texts, figures, software documentation, and reproducibility materials across the portfolio.

Author Novelty

The record includes distinctive methodological work linking sequence energetics, structural biology, network computation, and ribosome profiling. Novelty is substantial but distributed across collaborative projects, and the supplied evidence does not establish that every contribution was conceptually primary or field-defining.

Scientific Rigor

The directly reviewed dripARF work uses multiple analytical tests, benchmark and independent datasets, public code, and explicit falsification criteria. Rigor is reduced by dependence on indirect inference, RNase and protocol confounding, cross-species structural mapping, incomplete replication details, and the need for direct biochemical confirmation.